All ByHeart Whole Nutrition Infant Formula remains recalled as of April 2026. The recall covers every can ByHeart has produced since the brand's launch in March 2022. Clostridium botulinum was confirmed in finished product samples and traced through whole genome sequencing to organic whole milk powder in ByHeart's supply chain. 48 infants were hospitalised across 19 states. All survived.
The outbreak exposed a supply chain problem, not just a manufacturing problem. The contamination entered through an ingredient (milk powder), not at ByHeart's own factory. Even a brand doing everything right at the production stage can be undone by what happens upstream. The FDA subsequently found recalled product on shelves for weeks after the recall, in over 175 locations across 36 states.
If you have any ByHeart formula at home, any lot number, any product, do not use it. Contact your paediatrician if your baby has consumed ByHeart recently, even if seemingly well. Infant botulism symptoms can take up to 30 days to appear.
In November 2025, ByHeart, a brand that had built its reputation on being the cleanest, most transparent US formula, recalled every can it had ever produced. By February 2026, 48 infants had been hospitalised across 19 states. The FDA traced the contamination to organic whole milk powder in ByHeart's supply chain. All 48 infants survived. None died. But every single one required hospitalisation and treatment with BabyBIG, the only antidote for infant botulism, a drug produced exclusively by the California Department of Public Health.
This is not a story about a rogue brand cutting corners. ByHeart was, by most measures, doing everything right. Whole milk. No palm oil. No corn syrup. Third-party tested. Clinically studied. It was the formula many well-researched parents had concluded was the safest US option available. That is what makes this story worth reading carefully.
What is Clostridium botulinum, and why does it matter in formula?
Clostridium botulinum is a spore-forming bacterium found naturally in soil, dust, and, critically, in raw agricultural products. The spores themselves are not toxic. The danger occurs when spores are ingested by an infant, colonise the immature gut, and begin producing botulinum neurotoxin, one of the most potent biological toxins known to science.
Adults and older children can tolerate C. botulinum spores because their gut flora is developed enough to outcompete the bacteria. Infants cannot. Their guts are sterile and still developing, which is precisely why infant botulism is a disease that almost exclusively affects babies under 12 months.
Constipation is often the first sign. This is followed by poor feeding, drooping eyelids, sluggish pupils, loss of head control, weak cry, difficulty swallowing, and generalised muscle weakness. In severe cases: respiratory arrest. Symptoms can take up to 30 days to appear after exposure, which is why ByHeart formula continued causing cases for weeks after the recall began.
How did it get into organic whole milk powder?
This is the question the FDA has been working to answer since November 2025. What they have established, via whole genome sequencing, is that the same strain of C. botulinum Type A was found in: a can of ByHeart formula fed to a sick infant; finished product samples collected from ByHeart; the base mix used to make the formula; and most significantly, organic whole milk powder collected from Dairy Farmers of America, the processor for ByHeart's supplier, Organic West Milk.
The contamination appears to have entered the supply chain at the ingredient level, not at ByHeart's manufacturing facility. This distinction matters enormously. It means that even a formula brand doing everything right at the production stage can be undone by what happens upstream, on the farm, at the processor, or in the drying facility that turns liquid milk into powder.
Whole genome sequencing (WGS) is the same technology used to trace E. coli outbreaks to specific lettuce farms. It creates a genetic fingerprint of a bacterial isolate, accurate enough to confirm that the strain found in a sick infant's clinical sample is the same strain found in a can of formula, which is the same strain found in a batch of milk powder at a specific processing facility. The FDA's WGS analysis in this investigation provided exactly that chain of evidence, linking patient, product, and ingredient to a single origin.
The ByHeart inspection records nobody talked about
What emerged in the weeks following the recall was more troubling than the contamination alone.FDA inspection records from 2022 to March 2025, released during the investigation, showed a pattern of manufacturing and sanitation failures at ByHeart's facilities. At its Reading, Pennsylvania plant (now closed): mold, dead insects, and a leaking roof. At its Fullerton, Iowa plant: rodent activity, rusty surfaces, and positive environmental swabs for Cronobacter sakazakii, a pathogen that caused deaths in the 2022 Abbott formula crisis.
ByHeart had received a formal FDA warning letter in August 2023, two years before the recall, about contamination issues with a different bacterium entirely. The 2025 outbreak was not ByHeart's first encounter with the FDA's concern.
"The recalled formula continued to be found on store shelves, for over three weeks in one case, in over 175 locations across 36 states."
FDA press release, February 2026The recall itself became a secondary crisis. The FDA sent warning letters to Target, Walmart, Kroger, and Albertsons for failing to remove recalled ByHeart products from their shelves weeks after being notified. Investigators conducted over 4,000 spot-checks of retail stores across the US. Parents who had heard about the recall could not be certain the can on the shelf had been pulled. Parents who had not heard about it had no way of knowing at all.
What this tells us about supply chain traceability
ByHeart marketed itself on transparency. It published testing data. It completed a clinical trial, the first USDA organic whole milk formula to do so. It used whole milk, avoided palm oil, sourced from grass-fed cows. By the standards most clean-label parents apply when researching formula, ByHeart passed every test.
What the recall exposed is that ingredient-level traceability, knowing not just who makes your formula but who supplies their milk powder, and who processes that milk, and what safety systems exist at every point in that chain, is almost impossible for a parent to evaluate from a label. The label tells you what is in the tin. It does not tell you what happened before it got there.
EU organic certification requires that every ingredient in a certified organic product be traceable back through the supply chain to the farm. The European Food Safety Authority (EFSA) maintains a centralised system for tracking outbreaks and ingredient recalls that requires member states to share data within 24 hours. In the US, the FDA relies largely on voluntary reporting and company-initiated recalls. The ByHeart investigation revealed a system in which: the outbreak began as early as December 2023; was not formally investigated until November 2025; and saw recalled product remain on shelves for weeks after notification. This is not a criticism of ByHeart specifically. It is a structural observation about what US regulatory architecture can and cannot guarantee.
How ByHeart fits into the broader 2025-2026 formula safety story
The ByHeart outbreak was the first of three major infant formula safety events in six months. Each has a fundamentally different mechanism, and understanding the differences matters for how parents evaluate risk.
The ByHeart botulism outbreak was a supply chain failure at the ingredient level. Contaminated organic whole milk powder reached ByHeart from its dedicated supplier. Only ByHeart was affected because ByHeart was the only formula manufacturer using that specific supplier for that specific ingredient. The problem was traceability and oversight.
The cereulide contamination recall that began in December 2025 was a different kind of supply chain failure, one that affected multiple brands simultaneously. Contaminated ARA oil from a single Chinese supplier reached formula manufacturers globally, with recalls now spanning 99 countries according to the WHO. The problem was concentrated global ingredient sourcing with insufficient oversight.
The HiPP Austria incident in April 2026 was neither a supply chain nor a manufacturing problem. It was criminal tampering of jars on retail shelves in a single country. The mechanism was completely different from both ByHeart and cereulide.
The common thread across all three is that parents cannot evaluate these risks from a label. What a parent can evaluate is the regulatory system watching over how the formula got to the shelf. That is the argument for caring about regulatory architecture, not just ingredient lists. For the full picture of the 2025-2026 formula safety events, see our main coverage.
What parents should actually do
If you still have ByHeart formula at home, in any form, any lot, any date of manufacture, do not use it. Contact your paediatrician if your baby has consumed ByHeart recently, even if seemingly well, because symptoms can take up to 30 days to appear. The full brand production history is recalled.
If you are looking for a replacement, the most reliable signal is not marketing claims about ingredients. It is the regulatory system under which the formula was produced. EU organic certification requires traceability of every ingredient back to the farm of origin, and the European Rapid Alert System for Food and Feed (RASFF) mandates that member states share contamination information within 24 hours. The US has no equivalent mandatory system. That structural difference is what kept European formula brands out of both the ByHeart and cereulide events.
ByHeart was, by US standards, a clean formula. The lesson of this recall is that US standards may not be sufficient, and that the question parents should be asking is not just what is in the tin, but what regulatory system is watching over how it got there.
The ByHeart recall is not a story about a bad company. It is a story about a regulatory gap that a good company fell through. Supply chain contamination at the ingredient level, upstream of the manufacturer, is extremely difficult for any brand to catch, and almost impossible for a parent to assess from a label. The structural advantage of EU-certified formulas is not ingredient quality alone. It is the regulatory architecture that surrounds them: mandatory traceability, centralised surveillance, and a precautionary standard that the US system does not currently require. That is the gap this recall made visible.
"We recommend formulas with EU organic or Demeter biodynamic certification. Here is why that matters and which ones pass our full ingredient screen."
See our formula recommendations ✦